After finishing at $9.72 in the prior trading day, Caredx Inc (NASDAQ: CDNA) closed at $10.64, up 9.47%. In other words, the price has increased by $+0.92 from its previous closing price. On the day, 3481555 shares were traded. CDNA stock price reached its highest trading level at $11.09 during the session, while it also had its lowest trading level at $8.23.
Ratios:
Our goal is to gain a better understanding of CDNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On August 15, 2023, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 02 when Seeto Reginald sold 2,818 shares for $6.91 per share. The transaction valued at 19,483 led to the insider holds 479,164 shares of the business.
Seeto Reginald sold 2,819 shares of CDNA for $26,762 on Sep 05. The insider now owns 481,982 shares after completing the transaction at $9.49 per share. On Aug 14, another insider, Seeto Reginald, who serves as the insider of the company, sold 576 shares for $8.89 each. As a result, the insider received 5,123 and left with 484,801 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 525.84M and an Enterprise Value of 292.86M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.94 while its Price-to-Book (P/B) ratio in mrq is 1.46. Its current Enterprise Value per Revenue stands at 0.99 whereas that against EBITDA is -3.67.
Stock Price History:
Over the past 52 weeks, CDNA has reached a high of $16.54, while it has fallen to a 52-week low of $4.80. The 50-Day Moving Average of the stock is 10.02, while the 200-Day Moving Average is calculated to be 8.81.
Shares Statistics:
The stock has traded on average 1.06M shares per day over the past 3-months and 697.65k shares per day over the last 10 days, according to various share statistics. A total of 53.53M shares are outstanding, with a floating share count of 51.64M. Insiders hold about 4.54% of the company’s shares, while institutions hold 94.96% stake in the company. Shares short for CDNA as of Feb 15, 2024 were 3.6M with a Short Ratio of 3.41, compared to 2.37M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.65% and a Short% of Float of 8.66%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.27, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.14 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.46 and -$0.72 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.37, with 4 analysts recommending between -$0.25 and -$0.57.
Revenue Estimates
7 analysts predict $61.77M in revenue for the current quarter. It ranges from a high estimate of $64.4M to a low estimate of $58.2M. As of the current estimate, Caredx Inc’s year-ago sales were $77.26M, an estimated decrease of -20.10% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $268.7M, while the lowest revenue estimate was $250M, resulting in an average revenue estimate of $260.62M. In the same quarter a year ago, actual revenue was $280.32M, down -7.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $286.07M in the next fiscal year. The high estimate is $289.96M and the low estimate is $276.8M. The average revenue growth estimate for next year is up 9.80% from the average revenue estimate for this year.
